Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Grape Impact on Human Gut Microbiome

27. august 2026 oppdatert av: Gang Fang, Icahn School of Medicine at Mount Sinai

High-Resolution Assessment of California Table Grape Consumption on the Human Gut Microbiome-Immune Axis

This is a bio-specimen analysis and dietary intervention study that will examine whether the daily consumption of California table grape powder significantly modulates the gut microbiome and systemic immune profiles in healthy adults. The primary objective is to characterize longitudinal changes in microbial strains, metabolites, and immune markers following a 4-week grape intervention compared to a placebo. Methods include a screening of up to 300 individuals to evaluate pre-specified microbiome eligibility criteria, followed by a randomized, double-blind, placebo-controlled, parallel-group design where up to 40 participants will provide fecal and blood samples for high-resolution metagenomic sequencing and LC-MS/MS metabolomics at baseline, mid-study, and post-washout. Participants who meet the microbiome screening and other study eligibility criteria may be invited to participate in the intervention phase; participation in the screening phase does not guarantee enrollment in the intervention phase.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The human gut microbiome consists of trillions of microorganisms that are essential to host metabolism, immune system regulation, and the maintenance of disease resistance. Recent findings indicate that dietary changes can rapidly and significantly alter the composition of these microbial communities, leading to substantial effects on the host's overall physiology. Foods rich in polyphenols are highly effective at modulating this environment because they possess selective antimicrobial properties and exert beneficial prebiotic effects on the resident microbiota.

Polyphenol-rich foods beneficially modulate the human gut microbiome with downstream metabolic and immune effects. California table grapes contain a complex mixture of phenolics, resveratrol, flavans, flavonols, and anthocyanins, making them ideal candidates for investigating gastrointestinal and immune health. However, previous grape-microbiome studies have been limited by small sample sizes (n=21-29), short durations (2 weeks), low-resolution microbiome technologies (16S profiling), and failure to measure corresponding inflammatory or immune biomarkers.

This project will first conduct a microbiome screening phase in up to 300 healthy adults to identify individuals who meet pre-specified microbiome and other study eligibility criteria. Eligible individuals may then be invited to participate in a rigorous, multi-omic pilot study using standardized freeze-dried grape powder to determine how daily grape consumption modulates the gut microbiome-immune axis in up to 40 healthy adults. The study team will employ state-of-the-art metagenomic sequencing to achieve high-resolution microbiome profiling; metabolomic analysis; and immune biomarker profiling to assess gastrointestinal inflammation.

Specific Aims

Overarching Goal: To build on our unique expertise in high-resolution microbiome analyses to conduct a rigorous, multi-omic pilot study determining how daily consumption of California table grape powder modulates the human gut microbiome-immune axis in healthy adults.

Hypothesis: Compared to a placebo, daily consumption of California table grape powder will beneficially modulate the gut microbiome by: (1) altering microbial composition; (2) shifting the fecal metabolome to increase grape-derived and microbial-derived anti-inflammatory compounds; and (3) reducing baseline biomarkers of gastrointestinal inflammation.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Forente stater
    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine at Mount Sinai
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Gang Fang, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria

  • Healthy adults between the ages of 45 and 65 years old
  • Body Mass Index (BMI) within the range of 18.5 to 25.9 kg/m²
  • Willing and able to provide informed consent
  • Agreement to maintain usual dietary patterns throughout the study, except for the provided study powder
  • Agreement to avoid exclusion criteria (below) during the study period
  • Able and willing to collect and mail a stool sample during the microbiome screening phase and, if enrolled in the intervention phase, and at the three defined study timepoints
  • For enrollment into the intervention phase, meeting pre-specified microbiome eligibility criteria based on the screening stool sample, as defined in the study protocol.

Exclusion Criteria

  • Antibiotic use within 6 months prior to enrollment, or any planned antibiotic use during the study
  • Recent initiation of or dose change in any medication or supplement within 3 months prior to enrollment, or planned initiation or dose change during the study
  • Initiation or change of probiotic, prebiotic, or synbiotic supplements during the study. Existing long-term stable probiotic use is permitted
  • Current or recent (within 3 months) systemic corticosteroid, biologic, DMARD, chemotherapy, or other immunosuppressive therapy; regular NSAID use (more than 2 doses per week); or planned initiation of any of the above during the study
  • Active inflammatory bowel disease, irritable bowel syndrome with current symptoms, celiac disease, microscopic colitis, active diverticulitis, or acute gastrointestinal infection within 3 months; any history of C. difficile infection; or prior bariatric surgery or bowel resection
  • Uncontrolled or unstable chronic disease, including but not limited to uncontrolled diabetes (HbA1c >8%), chronic hepatitis B or C, cirrhosis, moderate-to-severe chronic kidney disease (eGFR <60), active or recent (within 5 years) malignancy, solid organ or bone marrow transplant, or uncontrolled cardiovascular or psychiatric illness
  • Planned major change in diet, physical activity, or lifestyle during the study period; recent significant weight change (>5% in 3 months); or current adherence to an extreme dietary pattern (strict vegan, ketogenic, carnivore, or very-low-carb) maintained for more than 3 months
  • Habitual high polyphenol intake, including daily consumption of more than 2 servings of berries, more than 500 mL of red wine, more than 4 cups of tea, or regular consumption of pomegranate, grape juice, or dark chocolate more than 3 times per week, as assessed by screening food-frequency questionnaire
  • Heavy alcohol use (more than 14 drinks per week), current tobacco use, or daily cannabis use
  • Known grape allergy or sensitivity; pregnancy, planned pregnancy, or breastfeeding during the study; current participation in other interventional clinical trials; or any condition that, in the investigator's judgment, would compromise study participation, compliance, or data interpretation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Grape Powder
Receive grape powder for consumption during intervention stage.
Kosttilskudd: Grape Powder
72 g of grape powder for daily consumption for 28 days.
Placebo komparator: Control
Receive placebo control powder for consumption during intervention stage.
Annen: Placebo Powder
72 g of matching placebo for daily consumption for 28 days.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Long read sequencing
Tidsramme: 3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Sequencing DNA from fecal samples to identify bacteria. This will assess whether the grape powder induces a change in the abundance of beneficial species/decrease in harmful species, following treatment, compared to control. This will be quantitatively assessed via sequencing.
3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fecal metabolites profile from LC-MS/MS
Tidsramme: 3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal metabolites as measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal calprotectin level measured by ELISA
Tidsramme: 3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal calprotectin as measured by ELISA. Elevated levels of calprotectin are a sensitive indicator of mucosal irritation.
3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal albumin level measured by ELISA
Tidsramme: 3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal albumin as measured by ELISA. Fecal albumin serves as a proxy for intestinal permeability, as its presence in the gut lumen suggests a leak across the epithelial barrier.
3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal Lipocalin-2 measured by ELISA
Tidsramme: 3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)
Fecal Lipocalin-2 as measured by ELISA. Fecal Lipocalin-2 is produced by both epithelial and immune cells in response to bacterial stressors.
3 collections at T0 (after 3 weeks of dietary control), at week 4 (after grape or placebo powder daily), and at week 8 (after 4 weeks of returning back to normal diet)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Icahn School of Medicine at Mount Sinai

Etterforskere

  • Hovedetterforsker: Gang Fang, PhD, Icahn School of Medicine at Mount Sinai

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

1. februar 2027

Studiet fullført (Antatt)

1. februar 2027

Datoer for studieregistrering

Først innsendt

27. august 2026

Først innsendt som oppfylte QC-kriteriene

27. august 2026

Først lagt ut (Faktiske)

1. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • STUDY-26-00544
  • IN300001209 (Annet stipend/finansieringsnummer: California Table Grape Commission)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All of the individual participant data collected during the trial, after deidentification.

IPD-delingstidsramme

Beginning 3 months and ending 5 years following article publication.

Tilgangskriterier for IPD-deling

Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. To achieve aims in the approved proposal.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere